Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors

Stefan Bidula, Izzuddin Bin Nadzirin, Marco Cominetti, Harry Hickey, Sean A. Cullum, Mark Searcey, Ralf Schmid and Samuel J. Fountain
Molecular Pharmacology January 2022, 101 (1) 33-44; DOI: https://doi.org/10.1124/molpharm.121.000402
Stefan Bidula
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izzuddin Bin Nadzirin
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Cominetti
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry Hickey
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean A. Cullum
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Searcey
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralf Schmid
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel J. Fountain
School of Biological Sciences (S.B., I.B.N., H.H., S.A.C., S.J.F.), and School of Pharmacy (M.C., M.S.), University of East Anglia, Norwich Research Park, United Kingdom; and Leicester Institute of Structural and Chemical Biology (R.S.), and Department of Molecular and Cell Biology (R.S.), University of Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    5-BDBD displays an allosteric mode of action (A) ATP-evoked Ca2+ responses from 1321N1 astrocytoma cells stably expressing human P2X2 (open circles) or P2X4 (closed circles; N = 6). (B) 5-BDBD inhibition (30-minute incubation) of P2X4 (closed circles) but not P2X2 receptors (open circles; N = 8). Both receptors activated with 1 μM ATP. (C) Effect of varying 5-BDBD concentrations (30-minute incubation) on ATP concentration-response relationship in 1321N1 astrocytoma cells stably expressing P2X4 (N = 6). (D) Sequential mutation of 10-amino-acid stretches in the ectodomain of P2X4 to the equivalent residues in P2X2 identified a region between residues 81 and 90 important for 5-BDBD activity. Substitutions between 71–80, 101–110, 131–140, 201–210, 221–220, 261–270, 281–290, and 291–300 produced nonfunctional chimeras (N = 5; * p < 0.05 ANOVA with Dunnett’s post hoc test). (E) Homology model of P2X4 in the ATP-bound (beige) open state based on zebrafish P2X4 (Protein Data Bank:4DW1). Residues 81–90 can be located toward the top of the body region (red) and extended toward the orthosteric site (blue).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Molecular modeling identified an allosteric binding site for 5-BDBD. (A) Representative 5-BDBD docking pose from molecular dynamics simulations. Relevant residues are shown as sticks, and potential hydrogen bonding is indicated by dashes. (B) Carbonyl-guanidine distances between 5-BDBD and R301 (blue) and R82 (red), respectively, for a representative molecular dynamics simulation. (C) Amide-carboxylate oxygen distances between 5-BDBD and E307. Blue and red represent the two carboxylate oxygens. (D) Distance between the Y300 hydroxyl group oxygen and the amide-NH (red) and carbonyl oxygen (blue). (E) Presence of hydrophobic interactions between 5-BDBD and relevant residues. For comparison residues are color-coded as in Fig. 3B.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Site-directed mutagenesis of the allosteric site identified F81, M109, F178, Y300, R301, and I312 as important residues for 5-BDBD inhibition (A) Alignment of amino acids predicted to interact with 5-BDBD in the binding site between P2X1-7 (P2X4 numbering). Blue and orange depict which subunit the amino acid residues are located on. (B) Inhibitory activity of 5-BDBD against mutant P2X4 receptors (N = 5; * p < 0.05 ANOVA with Dunnett’s post hoc test). (C) A representative image of 5-BDBD binding to the wild-type P2X4 receptor. Residues implicated in 5-BDBD (purple) binding are highlighted in red. (D) Representative images of 5-BDBD binding to the mutant receptors M109H, F178L, Y300A, R301K, and I312G. The mutated residue is labeled, and the distances between the amino acids and potential interactions with 5-BDBD are shown by dashes. Images were generated using Chimera.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    5-BDBD analogs identified key structural interactions between 5-BDBD and P2X4. (A) The structure of 5-BDBD and the positions of the halogen substitutions at R1, R2 and R3. Unmodified 5-BDBD has a bromine at position R2. (B and C) The IC50 values (B) and inhibitory activity (C) of the 5-BDBD analogs toward P2X4 stably expressed in 1321N1 astrocytoma cells (600 µM ATP and 30 µM 5-BDBD analog were used to quantify inhibitory activity; N = 3; * p < 0.05 ANOVA with Dunnett’s post hoc test). (D) The distance between the carbonyl group of 5-BDBD/5-BDBD analogs and R301 in the binding pocket as determined through docking studies. (E) The penetration distance of 5-BDBD/5-BDBD analogs into the predicted binding site relative to the opening of the pocket as determined by docking studies. Images were generated using Chimera.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Constriction of the P2X4 allosteric binding site in the open state may prevent the activity of 5-BDBD. (A) Representative image depicting the predicted constriction of the 5-BDBD binding pocket and conformational changes between P2X4 in the closed (blue) and open (red) states. (B) The relative distance between amino acids T76, S77, L79, R82, and W84 on one subunit with the atoms CD1 or CD2 of L107 on the other subunit in the closed and open channel. (C) Representative electrophysiology trace of a cell stimulated with 30 µM ATP in the absence of 5-BDBD (black) or after a 3-minute preincubation with 20 µM 5-BDBD (red). (D) Representative electrophysiology trace of cells stimulated with 30 µM ATP for 2 seconds prior to the addition of 30 µM ATP and 20 µM 5-BDBD (red) or ATP and DMSO (black) during the desensitization stage for 5 seconds. (E) Representative electrophysiology trace of cells stimulated with 30 µM ATP for 2 seconds prior to the addition of 30 µM ATP and 10 µM BX-430 (red), or ATP and DMSO (black), during the desensitization stage for 5 seconds. (F) The time constant values for current decay (τ) for the desensitization stage in the presence of DMSO, 5-BDBD, or BX-430. Traces and data are representative of 17, 7, and 5 cells for the vehicle control, 5-BDBD, and BX-430, respectively. *p < 0.05 vs. vehicle, **p < 0.05 vs. 5-BDBD. Images were generated using Chimera.

Additional Files

  • Figures
  • Data Supplement

    • Data Supplement -

      Supplemental Table 1. A summary of the distances between the atoms CD1 and CD2 of L107 on one subunit of P2X4, with the atoms of the indicated amino acid residues on the second subunit in both the closed and open state.

      Supplementary Figure 1. An overview of the chemical interactions between 5-BDBD and amino acid residues in the predicted allosteric binding pocket of P2X4. 

      Supplementary Figure 2. (A-C) Backbone root-mean-square deviation (rmsd) for three replicate molecular dynamics simulations of the extracellular domain of P2X4 with 5-BDBD docked into the allosteric site and (D) for the orthosteric control. (E-G). 

      Supplementary Figure 3. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at R2.

      Supplementary Figure 4. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at R3.

      Supplementary Figure 5. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at both R1 and R2.

      Supplementary Figure 6. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at R1.

      Supplemental information on synthesised compounds.

  • Data Supplement

    • Supplemental Data -

      Supplemental Table 1.  A summary of the distances between the atoms CD1 and CD2 of L107 on one subunit of P2X4, with the atoms of the inducated amino acid residues on the second subunit in both the closed and open state.

      Supplemental lTable 1.  A summary of the distances between the atoms CD1 and CD2 of L107 on one subunit of P2X4, with the atoms of the indicated amino acid residues on the second subunit in both the closed and open state.

      Supplementary Figure 1. An overview of the chemical interactions between 5-BDBD and amino acid residues in the predicted allosteric binding pocket of P2X4.  

      Supplementary Figure 2. (A-C) Backbone root-mean-square deviation (rmsd) for three replicate molecular dynamics simulations of the extracellular domain of P2X4 with 5-BDBD docked into the allosteric site and (D) for the orthosteric control. (E-G).  

      Supplementary Figure 3. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at R2.

       Supplementary Figure 4. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at R3.

      Supplementary Figure 5. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at both R1 and R2.

      Supplementary Figure 6. Representative images of the docking poses obtained for the 5-BDBD analogues with modifications at R1.

      Supplemental information on synthesised compounds.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 101 (1)
Molecular Pharmacology
Vol. 101, Issue 1
1 Jan 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Structural Basis of the Negative Allosteric Modulation of 5-BDBD at Human P2X4 Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

5-BDBD Antagonist Action through an Allosteric Site on P2X4

Stefan Bidula, Izzuddin Bin Nadzirin, Marco Cominetti, Harry Hickey, Sean A. Cullum, Mark Searcey, Ralf Schmid and Samuel J. Fountain
Molecular Pharmacology January 1, 2022, 101 (1) 33-44; DOI: https://doi.org/10.1124/molpharm.121.000402

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

5-BDBD Antagonist Action through an Allosteric Site on P2X4

Stefan Bidula, Izzuddin Bin Nadzirin, Marco Cominetti, Harry Hickey, Sean A. Cullum, Mark Searcey, Ralf Schmid and Samuel J. Fountain
Molecular Pharmacology January 1, 2022, 101 (1) 33-44; DOI: https://doi.org/10.1124/molpharm.121.000402
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics